Bayesian model of disease progression in GNE myopathy
- 3 December 2018
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 38 (8) , 1459-1474
Abstract
One Sentence Summary: A Bayesian repeated measures model based on quantitative muscle strength data from a prospective Natural History Study was developed to determine disease progression and design clinical trials for GNE myopathy, a rare and slowly progressive muscle disease.GNE myopathy is a rare muscle disease characterized by slowly progressive weakness and atrophy of skeletal muscles. To address the significant challenges of defining the natural history and designing clinical trials for GNE myopathy, we developed a Bayesian latent variable repeated measures model to determine disease progression. The model is based on longitudinal quantitative muscle strength data collected as part of a prospective Natural History Study. The GNE Myopathy Progression Model provides an understanding of disease progression that would have otherwise required a natural history of unfeasible duration. “Disease age,” the model‐generated measure of disease progression, highly correlates with a variety of clinical, functional and patient‐reported outcomes. With the incorporation of a treatment effect parameter to the GNE Disease Progression Model, we describe a novel GNE Myopathy Disease Modification Analysis that significantly increases power and reduces the number of subjects required to test the effectiveness of novel therapies when compared to more traditional analysis methods. The GNE Myopathy Disease Progression Model and Disease Modification Analysis can be applied to muscle diseases with prospectively collected muscle strength data, and a variety of rare and slowly progressive diseases.Keywords
Funding Information
- National Human Genome Research Institute
- National Center for Advancing Translational Sciences
- Clinical Center
This publication has 28 references indexed in Scilit:
- Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse modelNature Medicine, 2009
- Inclusion body myositis functional rating scale: A reliable and valid measure of disease severityMuscle & Nerve, 2008
- Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusion‐body myopathy muscleJournal of Neurochemistry, 2007
- Reduced sialylation status in UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase (GNE)-deficient miceGlycoconjugate Journal, 2007
- Distal Myopathy with Rimmed VacuolesThe American Journal of Pathology, 2005
- Hypoglycosylation of α-dystroglycan in patients with hereditary IBM due to GNE mutationsMolecular Genetics and Metabolism, 2004
- Muscular weakness assessment: Use of normal isometric strength dataArchives of Physical Medicine and Rehabilitation, 1996
- A comparison of three measures of disease progression in ALSJournal of the Neurological Sciences, 1996
- Quantitative motor assessment in amyotrophic lateral sclerosisNeurology, 1986
- “Rimmed vacuole myopathy” sparing the quadricepsJournal of the Neurological Sciences, 1984